Anand Shah, MD; Peter W. Marks, MD, PhD; Stephen M. Hahn, MD
free access
has multimedia
has audio
JAMA. 2020;324(10):931-932. doi:10.1001/jama.2020.15725
This Viewpoint from the FDA reviews the minimum safety and efficacy standards COVID-19 vaccine candidates would need to meet to be considered for approval, and affirms its commitments to evaluating both in diverse populations and to postmarketing surveillance as means to ensure that approval will meet the highest safety and regulatory standards based on science and evidence, not politics.
-
-
Conversations with Dr Bauchner:
Coronavirus Vaccine Update From the FDA
-
Editorial
Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine
Howard Bauchner, MD; Preeti N. Malani, MD, MSJ; Joshua Sharfstein, MD
JAMA
-
Conversations with Dr Bauchner:
COVID-19 Vaccine Approval and the FDA
-
Conversations with Dr Bauchner:
Coronavirus Update With Michael T. Osterholm, PhD, MPH
-
Conversations with Dr Bauchner:
Coronavirus Q&A With Anthony Fauci, MD – September 25, 2020
-
Conversations with Dr Bauchner:
Coronavirus Update With Anthony Fauci - October 28, 2020
-
Conversations with Dr Bauchner:
Coronavirus Vaccine Update With Anthony Fauci
Sonja A. Rasmussen, MD, MS; Muin J. Khoury, MD, PhD; Carlos del Rio, MD
free access
JAMA. 2020;324(10):933-934. doi:10.1001/jama.2020.14992
This Viewpoint provides examples of how applying precision public health operations can help curb the COVID-19 pandemic.
James M. Shultz, MS, PhD; Craig Fugate; Sandro Galea, MD, DrPH
JAMA. 2020;324(10):935-936. doi:10.1001/jama.2020.15398
This Viewpoint discusses the prospects for exacerbation of the coronavirus disease 2019 (COVID-19) pandemic during hurricane season in the US, and proposes reinforcement of public health measures, clear communication, and learning from each experience to reduce the risks of hurricane-related harms and increases in COVID-19 cases.
Daniel J. Morgan, MD; Laura D. Scherer, PhD; Deborah Korenstein, MD
has audio
JAMA. 2020;324(10):937-938. doi:10.1001/jama.2020.0354
This Viewpoint emphasizes the importance of precise language to help patients make evidence-informed decisions in shared decision-making, and argues that references to “chances of harms and benefits” will be more understandable to patients than discussions of “probabilities of risks and benefits.”
-
Conversations with Dr Bauchner:
Changing Language to Improve Physician Communication About Treatment Decisions
Kunal K. Sindhu, MD; Eli Y. Adashi, MD, MS
JAMA. 2020;324(10):939-940. doi:10.1001/jama.2019.21862
This Viewpoint reviews progress and challenges to date in federal and state efforts to transition combination oral contraceptives (COCs) from being prescription only to over-the-counter status in the US.